Comparison of the study groups with entire RA and SpA patients in terms of demographic data, disease-related features, TST and QFT-GIT results, and LTBI treatment rates

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Rheumatoid Arthritis** |  | **Spondyloarthritis** |  |
|  | **Study Group****(n=206)** | **Total****(n=2690)** | **p** | **Study Group****(n=392)** | **Total****(n=4995)** | **p** |
| **Female sex, %** | 77.7 | 79.3 | 0.602 | 39.3 | 43.8 | 0.086 |
| **Age, years** | 49±15 | 53±14 | **0.002** | 43±11 | 43±12 | 0.348 |
| **Education status, %**Primary or lowerHigher education | 45.254.8 | 5347 | **0.043** | 22.477.6 | 25.274.8 | 0.222 |
| **Smoking status, %** Never smoked Ex-smokerActive smoker | 64.417.318.3 | 58.917.923.2 | 0.260 | 41.717.141.2 | 39.819.440.8 | 0.514 |
| **Disease duration, years** | 11.8±8 | 12±8 | 0.718 | 8.7±6 | 9±7 | 0.675 |
| **Systemic steroid use, %** | 54.9 | 64 | **0.012** | 18.6 | 23.9 | **0.019** |
| **cDMARD use, %** Methotrexate Hydroxychloroquine Sulfasalazine Leflunomide | 83.566.545.153.436.9 | 8270.55845.945.9 | 0.6000.252**0.001****0.045****0.017** | 62.522.79.755.44.6 | 6627.911.658.16.9 | 0.164**0.026**0.2650.3010.085 |
| **TST, mm** | 5.7±5.8 | 6.7±6.9 | 0.164 | 9.3±6.4 | 10.2±7 | **0.015** |
| **TST, %** =0 mm ≥5 mm ≥10 mm≥15 mm | 28.644.218.47.8 | 28.847.928.311.7 | 0.9700.384**0.008**0.164 | 1169.139.315.3 | 11.572.745.418.6 | 0.7820.156**0.027**0.120 |
| **QFT-GIT, %** Positive Negative Indeterminate | 9.789.80.5 | 10.888.80.4 | 0.250 | 15.184.9- | 17.882.10.1 | 0.194 |
| **LTBI treatment, %** | 44.7 | 45.8 | 0.672 | 60.2 | 58.4 | 0.529 |

Continuous variables were given as means ± standard deviations. n= number; RA = rheumatoid arthritis; SpA = spondyloarthritis; cDMARD = conventional disease-modifying anti-rheumatic drug; TST = tuberculin skin test; QFT-GIT = Quantiferon®-TB Gold In-Tube; LTBI = latent tuberculosis infection